CordenPharma, the US-based pharma & biotech CDMO and a part of Astorg, a European private equity firm, has announced its largest investment to date with plans to spend around Euro 900-mn over the next three years at in its US and European site to grow its peptide technology platform.
These plans consist of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions designed and built according to the pharmaceutical industry’s most stringent quality and technical standards for short and long peptide manufacturing, including Biologics License Applications (BLA) requirements.
The US expansion involves bringing additional peptide capacity to the company’s Colorado site with the planned construction of a new large-scale manufacturing facility, and an additional increase in manufacturing trains in the existing facility.
The company said the move is in response to the “rapidly increasing demand in the diabetes and obesity glucagon-like peptide 1 (GLP-1) agonist medications market, and comes off the back of multiple, long-term, multiyear contracts totalling around Euro 3-bn, with potential upsides”.
The European expansion centres on the construction of a new greenfield facility, with the aim of creating additional peptide capacity to serve customers from initial early clinical to late-stage commercial manufacturing. “The new site will be located in the heart of Europe, fully-integrated within CordenPharma’s existing facility network,” the company said.
“Upon completion, the new constructions will be fully integrated within its network of cGMP manufacturing facilities, along with the dedicated technical and regulatory support by expert teams needed to secure innovators’ supply chains with small to large-scale fully-integrated services from APIs to drug products,’ the company said in a press note.
The growth plans aim to help the company reach the Euro 1-bn sales mark for its peptide platform, and around Euro 1.8-bn total group revenue by 2028. In the 2023 financial year, the company generated sales of Euro 880-mn.
Dr. Michael Quirmbach, President & CEO of CordenPharma Group commented, “We are honoured by the trust our customers have placed in us to deliver expert outsourcing for large multiyear contracts. In addition, the strong commitment and support of our shareholder Astorg demonstrates their strategic vision for CordenPharma to become the leading CDMO for complex modalities such as peptides, by offering fully-integrated end-to-end services from APIs to drug products (for both injectable and oral peptides).”


19 July, 2024 15:38:35 IST 
















